CDC42BPA and cancer: The inhibition of down-stream effectors, such as Rho-associated protein kinases (ROCK1 and ROCK2) and the myotonic dystrophy kinase-related Cdc42-binding kinase (MRCK), has emerged as a complementary strategy to suppress the metastatic features of cancer cells16–18; however, the therapeutic potential of most inhibitors has remained limited19.